Google
PHAR — PHARMING GROUP NV (Healthcare >> Biotechnology)
PHAR FAQ
What is PHAR's P/E ratio?
PHARMING GROUP NV (PHAR) currently trades at a P/E ratio of 49.45.
What is PHAR's ROE?
PHARMING GROUP NV reports a Return on Equity (ROE) of 4.58%.
What is PHAR's dividend yield?
PHARMING GROUP NV offers a dividend yield of 0.00%.
What is PHAR's Deepscope Quality Score?
Deepscope rates PHAR's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PHAR?
Deepscope's AI Timing Score for PHAR is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PHAR belong to?
PHARMING GROUP NV is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 12.47
Price
0.23
(1.88%)
Day Change
|
|
|---|
PHAR, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
50% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
3015
|
| Magic Formula Rank by ROE |
3015
|
| Magic Formula Rank by ROIC |
2556
|
| Price | 12.47 |
| PBV / Sector |
3.22 / 4.58
|
| Earning Per Share | 0.18 |
| PE / Sector |
49.45 / 17.10
|
| PEG or PE/Growth / Sector |
-0.48 / 0.52
|
| Average 1M Daily Value |
0.22 M
GREAT
|
| Average 1W Daily Value |
0.18 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:11:57 |
| Symbol | PHAR |
| Name | PHARMING GROUP NV |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 70.63 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 867.28 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Darwinweg 24, Leiden, Netherlands, 2333 CR
Phone: 31 71 524 7400
Website: https://www.pharming.com
Employees: 407
Sector: Healthcare >> Biotechnology
Description: Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
